Gene Expression Test for Monitoring Heart Transplant Rejection (AlloMap, MMDx Heart, myTAIHEART)
End-stage heart failure is a life-threatening condition, commonly a result of severe coronary artery disease, and can be treated with a heart transplant. It is estimated that over 2,000 patients will undergo heart transplants in the United States yearly, a number that will steadily rise in the future. Like other graft rejections, the risk of heart transplant rejection is very high and can manifest as hyperacute, acute cellular, antibody-mediated, or chronic. Acute cellular transplant rejection is the most common type of heart transplant rejection and occurs in 30-50% of transplant recipients within the first three to six months of transplant. Acute cellular rejection is diagnosed via histopathological and clinical assessment.
Studies have found a significant genetic influence on the occurrence of heart transplant rejection. As seen in the results from Cardiac Allograft Rejection Gene Observation (CARGO) trials showed that the expression of the genes correlated with transplant rejection is highly altered in patients with acute cellular heart transplant rejection. Based on these findings, the AlloMap assay has been developed to analyze the gene expression of the transplant rejection-associated genes. The AlloMap assay utilizes a polymerase chain reaction (PCR) technology that investigates the expression levels of 20 genes. 11 out of the 20 genes in the assay are related to heart transplant rejection and the rest are employed for normalization and internal quality control.
The 11 genes implicated in transplant rejection and analyzed via the AlloMap assay are ITGA4, PDCD1, MARCH8, WDR40A, PF4, C6orf25, IL1R2, ITGAM, FTL3, SEMA7A, and RHOU. These genes have been associated with various biochemical and immunological pathways responsible for transplant rejection. Based on the gene expression results, an AlloMap score is generated which indicates whether or not an endomyocardial biopsy is required. The AlloMap assay is highly recommended for individuals symptomatic of heart transplant rejection. The AlloMap assay has significantly aided in the reduction of endomyocardial biopsies required in patients, indicative of low-risk acute cellular heart transplant rejections.
- Useful in predicting heart transplant-associated acute cellular rejection
- Gives an indication of the requirement for an endomyocardial biopsy
The AlloMap assay interprets the risk of acute cellular rejection in terms of gene expression scores which ranges from 0 to 40.
- Low scores indicate that the patient is least susceptible to acute cellular rejection and an endomyocardial biopsy is not mandatory.
- Higher scores are suggestive of significant acute cellular rejection risk and therefore highly indicate the need for an endomyocardial biopsy.
Not applicable
Whole blood, Lavender-top (EDTA).
Stability
- Ambient: 1day
- Refrigerated: 3-5 days
- Frozen: 1 week
- Am J Transplant. 2006 Jan;6(1):150-60. [PMID: 16433769]
- Clin Transpl. 2008:35-43. [PMID: 19708444]
- Int J Nephrol. 2011;2011:180201. [PMID: 21845224]
- Expert Rev Cardiovasc Ther. 2017 Apr;15(4):307-313. [PMID: 28317398]
- Eur Heart J. 2016 Sep 1;37(33):2591-601. [PMID: 26746629]
- Circ Heart Fail. 2015 May;8(3):557-64. [PMID: 25697852]